Drew Ribadeneyra

Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma

S. Ely, R. Pearse, M. Coleman, 2021, American journal of hematology.

A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements

S. Parekh, S. Olcum, S. Wasserman, 2022, Communications Biology.

A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements

Clifford A Reid, S. Parekh, S. Olcum, 2022, Communications Biology.

CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies

Diana Abbott, Peter A Forsberg, T. Mark, 2023, Blood advances.